A monthly collection of diverse links covering AI developments and regulation, COVID origins debates, healthcare policy, cultural phenomena, scientific research, and internet curiosities, maintaining Scott's characteristic blend of serious analysis and entertaining observations.

A guest post defending the amyloid hypothesis of Alzheimer's disease, explaining why amyloid is likely the root cause despite recent criticism and discussing why early treatments have only been partially effective.

A detailed review of a 1995 paper introducing the PDAPP mouse model for Alzheimer's disease, examining how its limitations were overlooked and shaped decades of potentially misguided Alzheimer's research.

Scott analyzes the implications of the FDA ending compounded GLP-1 weight loss drugs, which have provided a cheaper alternative to official channels for the past three years, and examines various responses from both compounding pharmacies and pharmaceutical companies.

Scott explores GABA-A receptor subunits, their effects, and how various drugs interact with them, discussing potential for more selective drug development.

Scott Alexander examines Zulresso and Zuranolone, two neurosteroid drugs for postpartum depression, discussing their efficacy, challenges, and potential future applications.

Scott Alexander examines the development and effectiveness of vilazodone and vortioxetine, two antidepressants designed to work faster and better than SSRIs, but which ultimately failed to live up to expectations.

Scott Alexander humorously describes his observations at the American Psychiatric Association meeting, highlighting pharmaceutical influence, social justice focus, and historical context of psychiatry.

Scott explores the theory that clozapine's unique effectiveness in treating schizophrenia may be due to its combined action on dopamine and glutamate systems, potentially opening avenues for safer treatments.

Scott Alexander explores why recreational drugs like ketamine and MDMA have shown more promise in treating mental health conditions than intentionally developed pharmaceuticals, suggesting a new direction for drug research.

A collection of interesting links from early 2017 covering drugs, education, politics, science and history, with Scott's commentary on each.

A links roundup post covering recent developments in science, medicine, psychology and politics, with particular focus on research replication issues and the 2016 election season.

Scott Alexander compares the disconnect between American and Russian psychopharmacology to having different chemical elements, exploring why effective Russian psychiatric drugs are unknown in America.

Scott Alexander presents a satirical list of fictional drugs banned by the FDA, each with an absurd reason for its prohibition.

Scott presents a humorous list of fictional drugs banned by the FDA, each with unexpected and often ironic consequences.

Scott Alexander examines the life cycle of medical ideas, discussing how promising treatments often get stuck in a 'grey area' between proven and alternative medicine.

Scott Alexander presents a roundup of recent scientific and medical studies, covering topics from hallucinations to obesity genetics to schizophrenia treatment.

Someone rubs an old lamp and gets a genie, a bargain, and a chance to fix a problem that has defeated medicine for centuries. What happens next is the hard part.